AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2690-4861/268
Oncology department (Radiotherapy Department) of Zhe Jiang Hospital, Hangzhou, Zhejiang, China
*Corresponding Author: Zhi-Bing Wu, No. 1229, Gudun Road, Xihu District, Hangzhou City, Zhejiang Province, China
Citation: Lei L., Li-T. Chen, Lai J., Zhi-B. Wu (2022). The Role of PFKFB3 In the Tumor Microenvironment and Its Therapeutic Potential. International Journal of Clinical Case Reports and Reviews. 12(2); DOI:10.31579/2690-4861/268
Copyright: © 2022 Zhi-Bing Wu, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 19 October 2022 | Accepted: 24 October 2022 | Published: 16 November 2022
Keywords: glucose metabolism; warburg effect; 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase; glucose metabolism ; metabolic reprogramming
Energy metabolic reprogramming has recently been recognized as an important hallmark of tumor metabolic biology, and tumor cells can be manipulated to obtain rapid growth, immune evasion and apoptosis, which play an important role in tumor development. Enhanced glycolysis is the main source of energy required for tumorigenesis, development and metastasis in the tumor microenvironment, and Warburg suggested that tumor cells preferentially choose glycolysis as the main pathway to provide energy even under aerobic conditions, but the mechanisms and causes of this metabolic alteration remain unclear. PFKFB3 is an important activator of glycolysis and plays an important role in carcinogenesis, including Tumor cytogenesis, metastasis, drug resistance and alteration of the tumor microenvironment. In this review, we summarize the role of PFKFB3 in different tumor types and its effects on the tumor microenvironment, as well as the signaling pathways through which PFKFB3 acts in tumors, suggesting PFKFB3 as a potential anti-tumor therapeutic target.
The "Warburg effect", first proposed by the German scientist Otto Warburg in the early 1920s [1,2], It is that tumor cells preferentially choose glycolysis as the main metabolic pathway to provide energy even under adequate oxygen conditions. The level of glycolytic flux is regulated by different mechanisms, including three key enzymes, namely hexokinase, phosphofructokinase-1 (PFK-1) and pyruvate kinase [3]. One of the key steps is the conversion of fructose-6-phosphate (F6P) to fructose-1,6-phosphate(F1,6P2). 6-phosphofructo-1-kinase, for which F-1,6-BP, ADP, and AMP are metabolic activators. Its activity is regulated by adenosine triphosphate (ATP), adenosine diphosphate (ADP), and fructose-2,6-phosphate (F-2,6-BP) [4]. The level of Fru-2,6-P2 in tumor cell glycolysis is mainly regulated by PFKFB3, a hallmark of malignancy that is susceptible to regulation by isoforms characterized by high kinase/phosphatase ratios. The PFKFB3 gene has the highest kinase/phosphatase activity in the PFKFB gene family and is used to maintain high glycolytic efficiency [5,6]. (Figure 1)
Figure1: The role of PFKFB3 in glycolysis is illustrated by the regulation of PFK-1: PFKFB3 promotes glycolysis by activating F-2,6-BP.
The PFKFB gene consists of four different isozymes (PFKFB1-4) [7], which are highly homologous, among which the PFKFB3 gene is located on the short arm of chromosome 10p14-15 [8] and was first isolated in the bovine brain library [9], in which the pfkfb3 gene consists of 19 exons including 7 variable regions and 12 constant regions The kinase/bisphosphatase activity is 700-fold higher than that of the isozyme and facilitates the synthesis of Fru-2,6-P2 [10,11]. This PFKFB3 protein has two distinct functional domains: the C-terminal domain of the diphosphatase activity of the enzyme, which degrades F2,6P2 to F6P and inorganic phosphate (Pi), and this structural domain can be selectively spliced to produce six isoforms from UBI2K1 to UBI2K6. the N-terminal domain is responsible for the synthesis of F2,6P2 from F6P and ATP. the PFK-2/FBPase2 bifunctional enzyme is the gene product enzyme of PFKFB3 and is regulated by covalent modifications. the C-terminal structural domain can be phosphorylated at Ser461 by different protein kinases [12]. (Figure2, Figure3)
Figure2: PFKFB3 gene structure:The PFKFB3 gene contains 19 exons, which are divided into a constant region and a variable region. The variable region contains seven exons from A-G.
Figure3: PFKFB3 protein structure: The PFKFB3 protein has two homodimeric subunits, each containing an N-terminal kinase domain and a C-terminal phosphatase domain. the N-terminal catalyzes the production of F2,6P2 and ADP from F6P and ATP, which highly promotes the glycolytic pathway. the C-terminal dephosphorylates F2,6P2 to produce F6P and Pi.
1.Targeting PFKFB3 in immune cells
Warburg effect is associated with the regulation of immune cell metabolism, and both immune cells and tumor cells are considered as highly motile cells that preferentially select glycolysis for energy supply, and by exploiting the possibility of regulating the metabolism of cancer cells and antitumor immune cells by metabolic differences between different cells, glycolysis can be used as a metabolic checkpoint for cancer immunotherapy. Chen [13] et al. found that monocytes in the tumor microenvironment significantly increased the glycolytic flux of cells in the paracancerous region of HCC (hepatocellular carcinoma). The activation of glycolysis induced PD-L1 expression on cells in the peritumoral region of HCC, thereby attenuating cytotoxic T lymphocyte infiltration. The key glycolytic enzyme PFKFB3 can be upregulated by soluble factors such as hyaluronic acid. PFKFB3 not only acts as a cellular glycolytic switch, but also mediates increased PD-L1 expression through activation of the nuclear factor kappa B signaling pathway. PFKFB3/CD68 infiltration in hepatocellular carcinoma paraneoplastic tissues was negatively correlated with overall survival of HCC patients and was an independent prognostic factor for survival of HCC patients. The role of PFKFB3 in T lymphocyte-mediated immune-related antitumor immunotherapy is still poorly investigated. Zhang [14-16] et al. found that PFKFB3 inhibitor PFK-158 increased infiltrating CD8+ and CD4+ T cells and decreased infiltrating Th17 cells in melanoma mice. Glycolytic reprogramming is associated with immune activation responses and immune tolerance in the tumor environment and is a potential target for future immune-based anticancer therapies.
2. PFKFB3 and ECs
Tumors are rich in blood vessels with irregular morphology, which provide nutrition for tumor development and metastasis and are associated with poor prognosis, and pathological angiogenesis is one of the characteristic hallmarks of tumors [17,18]. Under conditions such as hypoxia, vascular endothelial growth factor (VEGF) in vascular endothelial cells can stimulate neovascularization by regulating PFKFB3 expression [19,20], and regulate directed migration of vascular endothelial cells to promote neovascularization and endothelial migration. [21].
In contrast to conventional anti-angiogenic therapies aimed at reducing angiogenesis, it is the normalization of the characteristically disorganized tumor vascular system to improve blood perfusion, which may reduce hypoxia and increase drug accessibility. Normalized blood vessels may also resist the shedding of cancer cells in the primary tumor, which may reduce tumor metastasis. A recent study found that inhibition of PFKFB3 in melanoma tumor vascular endothelial cells (TEC) induced normalization of tumor blood vessels, thereby reducing tumor angiogenic activity and contributing to increased sensitivity to antitumor drugs. Improving vascular permeability by reducing VE-calmodulin endocytosis thereby reducing angiogenic activity [22,23]. By reducing NF-κB signaling, TECs also decrease the expression of cancer cell adhesion molecules and inhibit metastasis of cancer cells [24]. Therefore, targeting EC metabolism by PFKFB3 may provide novel therapeutic perspectives for anti-angiogenic therapy and inhibition of tumor growth.
3. PFKFB3 and autophagy
In 1963 Christian de Duve elucidated the mechanism of the process from yeast to cultured cell lines into mice,
The concept of autophagy was first proposed [25], which consists of five distinct phases: initiation, vesicle nucleation, vesicle elongation, vesicle fusion and material degradation, regulated by ancient and highly conserved genes that act during stresses such as oxidative stress, hypoxia and nutrient deprivation [26,27]. Autophagy is an organelle-dependent process that transports substances to lysosomes for degradation, ensures the cell cycle and provides energy to the cell. Autophagy presents a double-edged role in tumors depending on the tumor microenvironment: it can be both a tumor suppressor mechanism and a promoter of tumor cell survival. For example, in renal cell carcinomas, PFKFB3 accumulation in the cytoplasm promotes ATP production and thus inhibits autophagy in renal cell carcinoma (RCC) cells, whereas nuclear localization of PFKFB3 is associated with enhanced autophagy in tumor cells [28]. Self-renewal of breast cancer stem cells is an important process in the resurrection of breast cancer after metastatic dormancy, PFKFB3 plays an important conditional role in breast cancer metastatic recurrence, Alyssa La Belle Flynn observed an inverse relationship between PFKFB3 expression and autophagy, disruption of autophagy timing drives PFKFB3 to be able to drive dormant BCSC and metastatic lesion recurrence The phenotypic shift from a metastatic dormant state to tumor recurrence from high PFKFB3low autophagy to low PFKFB3 high autophagy was observed, and the detection of PFKFB3 and autophagy expression status could predict tumor recurrence and the response status of tumor patients to treatment[29].
4. PFKFB3 and Tumor drug resistance
The mortality rate of hepatocellular carcinoma is extremely high worldwide, largely due to the lack of effective and durable therapeutic measures. [30] Sorafenib is the first generation of targeted therapy for hepatocellular carcinoma and is considered to be of benefit to patients, however, because of the early onset of sorafenib resistance, most patients do not receive a long-term benefit. Li et al. showed that aspirin combined with sorafenib could induce death of sorafenib-resistant cancer cells without associated hepatotoxicity and inflammatory responses by inhibiting PFKFB3 to reduce glycolytic flux to make mitochondrial permeability, and by making metabolites such as lactate decrease to activate associated apoptotic signals. It is shown that PFKFB3 overexpression dominates the resistance process of sorafenib in hepatocellular carcinoma and can be controlled by inhibiting PFKFB3 expression through aspirin as a target. In hepatocellular carcinoma sorafenib enhances glucose uptake and lactate export in hepatocellular carcinoma cells [31]. It has been shown that glycolysis inhibitors such as inhibition of PFKFB3 can greatly inhibit the growth of sorafenib-resistant cells to increase glycolytic flux and enhance glycolysis [32,33]. Silencing of PFKFB3 enzyme has a synergistic effect with sorafenib [34,35,36]. Inhibition of glycolysis by specific molecules or targeting key enzymes of glycolysis is an effective strategy to attenuate sorafenib resistance.
Cisplatin is the first widely used chemotherapeutic agent in solid tumors such as head and neck tumors, lung cancer, bladder and reproductive tumors, where the mechanism of action is mainly to induce DNA damage in tumor cells leading to cell cycle arrest and induction of apoptosis. Demonstrated that PFKFB3 has a key role in protecting tumor cells from chemotherapeutic drug-induced apoptosis. Cisplatin-induced DNA damage induces PFKFB3 acetylation at lysine 472 (K472), and acetylation at Lys472 of PFKFB3 protein contributes to the cytoplasmic accumulation of PFKFB3 by weakening the interaction between input protein α5 and PFKFB3. This increases the phosphorylation of PFKFB3 at the Ser461 site. This is known to be associated with enhanced glycolytic activity. Cisplatin-induced DNA damage stimulates PFKFB3 Lys472 acetylation in an ATM-dependent manner, promoting enhanced glycolysis and protecting cells from cisplatin-induced apoptosis. This is critical for the cellular response to DNA damage caused by chemotherapeutic agents. A novel mechanism for acetylation-mediated PFKFB3 accumulation in the cytoplasm regulating cisplatin antitumor was revealed, and a potential strategy for chemotherapy by targeting PFKFB3 was proposed[37].
5. regulation mechanism
The mechanisms regulating PFKFB3 are different for different environments and different regulatory factors(Table1). For example, progesterone, stress stimulation or insulin trigger a dual mechanism to ensure that glycolysis increases phosphorylation and activation of PFKFB3 enzymes in acute environmental situations [38,39]. Activation of different kinases in hypoxic, ischemic or stressful microenvironments may be critical for cell survival and therefore represent a protective mechanism for cells in stressful states or hypoxic environments.HIF-1, AMPK and other kinases are components of a concerted cellular response to maintain energy homeostasis in hypoxic, stressful or ischemic microenvironments [39, 40,41].PFKFB3 is subject to Demethylation [42] or ROS-mediated S glutathionylation [43] is regulated in cancer cells, resulting in tumor cells primarily utilizing the pentose phosphate pathway for metabolism rather than the glycolytic pathway, which allows for ROS detoxification. p53 represses PFKFB3 gene expression to increase glucose passage through the pentose phosphate pathway to increase nucleotide production, thereby promoting nucleotide biosynthesis in response to DNA damage [44].
Table 1
The oncogenic Ras signaling pathway is a central regulator of glucose metabolism for cancer and can regulate PFKFB3 activity. Ras in glioblastoma inhibits glycolysis by reducing pfkfb3 gene expression through inhibition of hypoxia-inducible factor 1 α (HIF-1α) [39]. [45] Constitutive HER2 expression increases PFKFB3 expression and glucose metabolism in breast cancer cells. Hypoxia, progesterone, and estradiol can induce PFKFB3 expression through the interaction of HIF-1, progesterone receptor (PR), and estrogen receptor (ER) with their shared response elements located in the pfkfb3 promoter. It was shown that the circadian rhythm-driven transcription factor 'CLOCK' can bind to the pfkfb3 promoter at the 'E-box' locus to increase pfkfb3 transcription in cancer cells, PFKFB3 inhibition significantly delays the growth of implanted human tongue cancer cells in mice only at certain time points within the circadian cycle [46]. This finding suggests the importance of time-based PFKFB3 inhibition in cancer therapy. The major signaling pathways involved in PFKFB3 regulation were shown to be in (Figure4)
Figure4: Numerous signaling pathways that regulate PFKFB3. [1] Progesterone, estradiol and hypoxia induce the transcription factors PR, ER and HIF to bind to their response elements at the PFKFB3 promoter, respectively. [2] Stimuli such as stress increase PFKFB3 production through the P38/MK3 pathway. eGF acts through the ERK1/2 (extracellular signal-regulated kinase)/RSK1-4 (ribosomal S6 kinase) pathway, and [3] the TGF-β/Smad pathway regulates PFKFB3 expression
6. PFKFB3 role in tumor proliferation and invasion
Atsumi et al. showed that PFKFB3 mRNA G1/S cell cycle phase was induced to promote tumor cell proliferation [47]. In line with these findings, Calvo et al. found a significant decrease in tumor growth rate by silencing PFKFB3siRNA in HeLa adenocarcinoma cervical cancer cells [48]. Furthermore, Yalcin et al. showed that PFKFB3 knockdown induced cell cycle arrest at G1/S in HeLa cells [49]. The pro-proliferative role of PFKFB3 in the tumor cell cycle was confirmed.
PFKFB3 expression was also negatively correlated with many proteins involved in epithelial-mesenchymal transition (EMT). Gu M et al. showed that knockdown of PFKFB3 in nasopharyngeal carcinoma cells revealed up-regulated expression of E-cadherin and down-regulation of Vimentin and N-cadherin levels [50]. In addition, it has been shown that PFKFB3 siRNA transfection reduced Snail expression while upregulating E-cadherin levels in pancreatic cancer cells [51]. Our previous study showed that PFKFB3 upregulated expression in gastric cancer cells correlated with gastric cancer EMT. aberrant PFKFB3 expression and tumor invasion and metastasis.
With the accumulation of knowledge about the role of PFKFB3 in tumor metabolic reprogramming, there has been a strong interest in PFKFB3 inhibitors in antitumor therapy(Table2). To date, [52,53] the best-known PFKFB3 inhibitor is 3PO, a 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, also known as 3PO, synthesized by Clem et al. 3PO inhibits a variety of tumor cells by inhibiting recombinant PFKFB3, decreasing 3PO inhibits a variety of tumor cells by inhibiting recombinant PFKFB3, reducing glucose uptake and decreasing cytoplasmic levels of Fru-2,6-P and ATP, thereby attenuating tumor cell activity. PFKFB3 expression was increased in HER2-positive breast cancer, and PFKFB3 expression was associated with poorer progression-free and metastasis-free survival in breast cancer patients [45].PFK15 showed greater inhibitory activity against PFKFB3, rapidly induced apoptosis in transformed cells, displayed adequate pharmacokinetic properties, inhibited glucose uptake and 20 Promoted Lewis in syngeneic mice lung cancer growth in syngeneic mice and exerted antitumor effects in thymus-free mice against three human cancer xenograft models [54].
Table 2
PFK15 is the only PFKFB3 inhibitor used in phase I clinical trials, and a phase I clinical trial of PFK158 in patients with advanced solid malignancies was completed in 2016, confirming the efficacy of PFK158 in a variety of advanced solid malignancies. PFK158 has been shown to be safe and protective in a variety of advanced solid tumors, demonstrating its important clinical utility as monotherapy or in combination with other targeted agents (clinicaltrials.gov #NCT02044861) [55,56,57].
In this review, we summarize the current knowledge on the role of PFKFB3 in tumor cell metabolism and the mechanisms of PFKFB3 action. The intriguing links between PFKFB3 and tumors, and between ECs and immune cells, suggest that PFKFB3 is a potential target for tumor therapy. However, to date, no PFKFB3 inhibitors have been approved for the treatment of cancer patients. 3PO is a potent inhibitor of PFKFB3, but poor water solubility makes this compound clinically unusable, and the recent emergence of nanotechnology-based drug delivery vehicles has the ability to formulate a variety of hydrophobic anticancer agents, including 3PO, thus showing potential to enhance anticancer effects when used in vivo. PFKFB3 represents a promising target for tumor therapy. However, to date, no PFKFB3 inhibitors have been approved for the treatment of cancer patients. 3PO is a potent inhibitor of PFKFB3, but poor water solubility has prevented the clinical use of this compound. Other potent and selective PFKFB3 inhibitors, such as PFK15 and PFK-158, are in clinical trials in patients with advanced tumors. Nanotechnology-based drug delivery vehicleswere formulated into various hydrophobic anticancer agents, including 3PO, thus showing potential to enhance anticancer effects when used in vivo.The relationship between PFKFB3 as a metabolic regulatory switch and tumor immunity suggests that targeting tumor metabolism and targeting immunity to treat tumors provides new insights.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
